Multiple U.S. IPOs are scheduled to price and begin trading in mid-October 2026, including Iambic Therapeutics (IAM) targeting $150 million on October 15 and City Therapeutics (CTY) seeking $175 million on October 16, with additional smaller deals and filings advancing through November. Biotech and select growth names continue to access the public market amid steady aftermarket performance from recent pricings, while larger AI-related candidates such as Anthropic remain in confidential or advanced stages with potential Q4 windows. Equity market conditions, including Treasury yields and risk appetite, support episodic deal flow rather than a broad reopening, but the near-term calendar ensures listings will occur well before year-end. Trader consensus on near-certainty outcomes reflects these concrete schedules and ongoing S-1 activity over the next 60–80 days.